🟢 MEDPAL AI is trading 12.24% up today after FDA expands Mounjaro’s cardiovascular indication

MEDPAL AI is trading 12.24% up at £5.50 after highlighting the FDA’s August 28, 2026 approval allowing Mounjaro to reduce major cardiovascular events in certain high-risk adults with type 2 diabetes.

• The expanded GLP-1 indication could enlarge the addressable patient population for MedPal’s New Health clinic.
• An external quote page reported 20,372,121 shares in volume; broader markets were broadly supportive but not the primary catalyst.
• The decision does not yet change Mounjaro’s UK prescribing authorisation.